Svenska
August 24th, 2018

Immunovia Interim report, January-June 2018

Key Indicators

Key Indicators
(SEK thousand unless otherwise stated)
1 Apr-     30 June 2018 1 Apr-     30 June 2017 1 Jan-     30 June 2018 1 Jan-     30 June 2017 Full year 2017
Net sales 44 68 156 95 149
Operating earnings –27,232 –10,645 –44,608 –18,515 -45,520
Earnings before tax –26,147 –10,554 –43,473 –18,325 -45,232
Net earnings –26,154 –10,554 –43,480 –18,325 -45,232
Earnings per share before and after dilution (SEK/share) –1.47 –0.63 –2.47 –1.09 -2.67
Equity ratio, % 96 96 96 96 94
No. of shares at the end of the period 19,480,853 16,804,059 19,480,853 16,804,059 17,318,059
Average no. of shares before and after dilution 17,846,742 16,804,059 17,582,400 16,804,059 16,932,559

This financial statement has been produced in accordance with IFRS for the Immunovia Group, which comprises Immunovia AB and the wholly-owned subsidiaries Immunovia Inc. and Immunovia GmbH.


Outlook
Immunovia is focused on fundamentally transforming diagnosis of complex forms of cancer and autoimmune diseases. The antibody-based platform, IMMray™, is the result of 15 years of research at CREATE Health – the Center for Translational Cancer Research at Lund University, Sweden. IMMray™ is a technology platform for the development of diagnostic tests and the company’s primary test, IMMray™ PanCan-d, is the first test in the world for early diagnosis of pancreatic cancer.

The company’s financial targets remain in place, but have been delayed in relation to previous announcements, due to the need to perform optimization studies. The company expects to receive the first revenues from self-pay sales in the latter part of 2019.

The following financial targets have been established:

• Immunovia’s target is to achieve turnover of SEK 250-300 million by 2022 based on self-pay for IMMray™ PanCan-d.

• Immunovia’s target is to achieve total turnover, including payment via self-pay and cost remuneration from insurance systems, of SEK 800-1,000 million by 2024.

This information is information that Immunovia AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 24 August at CET 08:30, through the agency of the contact person set out above.  

For further information, please contact:
Mats Grahn, CEO, Immunovia AB
Phone: +46 (0) 70-532 02 30
E-mail: mats.grahn@immunovia.com

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

 

 

Download PDF File

Subscribe

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form. Please check the junk mail if you cannot find the message.

Press releases
Financial reports